Puma Biotechnology Inc (NASDAQ: PBYI) is a biopharmaceutical company that develops and commercializes drug candidates for the treatment of cancer. The company generates revenue from product sales of its approved oncology therapeutics. Puma Biotechnology trades on the NASDAQ Global Select Market, as disclosed in its 10-K filed February 26, 2026. The filing excerpts provided do not contain sufficient detail to specify segment revenue figures, key product names, customer concentration, geographic mix, founding year, current CEO tenure, or named competitors with support from the source document. Based solely on the available filing excerpts, the company is a small-cap biopharmaceutical issuer, with common stock carrying a closing price of $3.43 per share as of June 30, 2025, and is not classified as a well-known seasoned issuer under SEC Rule 405.

Revenue model

The filing excerpts do not provide sufficient detail to describe the revenue model with specificity.

Products and services

The filing excerpts do not name specific products or services with enough detail to summarize.

Customers and end markets

The filing excerpts do not provide customer or end market detail sufficient for description.

Value-chain role

Biopharmaceutical developer and commercial-stage drug company in oncology.

Geographic exposure

The filing excerpts do not specify geographic revenue mix.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Annovis Bio Inc BIORA THERAPEUTICS, INC. Atossa Therapeutics Inc Candel Therapeutics Inc Decibel Therapeutics, Inc. INFINITY PHARMACEUTICALS, INC. Inozyme Pharma, Inc. Tourmaline Bio, Inc.